FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

doi:10.3748/wjg.v18.i33.4533

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4968)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

575

HTML

4097

Figures (1-2)

136

Tables (1-4)

160

Sum=4968

Sep 7, 2012 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 7, 2012; 18(33): 4533-4541
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4533

Full Size Figure Download Figure

Figure 1 Time to progression (A) and overall survival (B) from the beginning of FOLFIRI for the 63 patients. TTP: Time to progression; OS: Overall survival.

Citation: Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541
URL: https://www.wjgnet.com/1007-9327/full/v18/i33/4533.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i33.4533